ClinVar Miner

Submissions for variant NM_000548.5(TSC2):c.5320A>G (p.Ser1774Gly)

gnomAD frequency: 0.00001  dbSNP: rs368083145
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000535476 SCV000644631 benign Tuberous sclerosis 2 2023-12-30 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV001821554 SCV002071968 uncertain significance not specified 2021-11-04 criteria provided, single submitter clinical testing DNA sequence analysis of the TSC2 gene demonstrated a sequence change, c.5320A>G, in exon 42 that results in an amino acid change, p.Ser1774Gly. This sequence change does not appear to have been previously described in individuals with TSC2-related disorders. This sequence change has been described in the gnomAD database in two individuals which corresponds to a population frequency of 0.00071% (dbSNP rs368083145). The p.Ser1774Gly change affects a poorly conserved amino acid residue located in a domain of the TSC2 protein that is not known to be functional. The p.Ser1774Gly substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Ser1774Gly change remains unknown at this time.
Ambry Genetics RCV002350300 SCV002647275 uncertain significance Hereditary cancer-predisposing syndrome 2023-08-09 criteria provided, single submitter clinical testing The p.S1774G variant (also known as c.5320A>G), located in coding exon 41 of the TSC2 gene, results from an A to G substitution at nucleotide position 5320. The serine at codon 1774 is replaced by glycine, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.